Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary ...

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases INGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

By: Kristine Pascual, March 11, 2025 Cal Poly Pomona’s College of Business Administration has found a way to make research boring, lifeless and disconnected by allowing artificial intelligence to do ...

McKinsey's Design Index shows companies with strong design practices outperform industry benchmarks by as much as 2-to-1. In ...

The Phase 1 trial is an open label, dose ranging clinical study designed to evaluate Vaxart’s second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.

Strasbourg (France), March 11, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today ...

Goodbye, clean and traditional hardwood. Welcome, a court emblazoned with hundreds of “XII” logos resulting in a polarizing ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and ...

Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered ...

G. Willi-Food International Ltd. (the 'Company' or 'Willi-Food'), a global company that specializes in the development, marketing and international distribution of kosher foods, today announced that ...

The Fashion Institute of Technology (FIT) announces that FIT President Joyce F. Brown will be honored, in recognition of her ...